Yanai Shlomo 4

What Happened
Yanai Shlomo, a director of Amneal Pharmaceuticals (AMRX), had restricted stock units (RSUs) convert to common shares in early May 2026. The Form 4 reports conversion/exercise of 34,819 RSUs (derivative) on May 7, 2026 and shows a net receipt of 19,824 shares (reported as an award/acquisition on May 6, 2026) at $0.00. The filing also records a related disposition of shares in connection with the conversion—consistent with shares being withheld/used in settlement—resulting in the net 19,824 shares delivered to the insider. No cash purchase or open-market sale proceeds are reported.

Key Details

• Transaction dates: May 6, 2026 (award reported) and May 7, 2026 (conversion/exercise).
• Reported amounts: 34,819 RSUs converted; 19,824 shares acquired (net); the difference (14,995 shares) is shown as a related disposition in the filing.
• Prices/values: all entries reported at $0.00 or N/A (derivative conversion/net settlement, not an open-market purchase or sale).
• Footnotes: (F1) each RSU = right to one Class A common share; (F2) the 34,819 RSUs were originally granted May 6, 2025 and vested May 7, 2026; (F3) vesting was subject to the issuer's post-grant timing conditions.
• Shares owned after transaction: not specified in the filing.
• Timeliness: Form 4 was filed May 8, 2026 and appears timely relative to the May 6–7 transactions.

Context
This was a routine RSU vesting/conversion and net settlement event (a derivative transaction), not an open-market purchase or sale that signals new buying or selling conviction. The disposition recorded in the filing is consistent with shares being withheld or transferred to satisfy withholding/settlement obligations upon vesting.